Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study

BACKGROUND: Eribulin is a non-taxane, microtubule dynamics inhibitor that increases survival of patients with metastatic breast cancer. Although eribulin is well tolerated in patients with heavily pretreated disease, eribulin-induced liver dysfunction (EILD) can occur, resulting in treatment modific...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Kobayashi, Takayuki, Tomomatsu, Jyunichi, Fukada, Ippei, Shibayama, Tomoko, Teruya, Natsuki, Ito, Yoshinori, Iwase, Takuji, Ohno, Shinji, Takahashi, Shunji
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4936231/
https://ncbi.nlm.nih.gov/pubmed/27389013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2436-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados